CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

In the preceding three months, 12 analysts have released ratings for Vertex (NASDAQ:VERX), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

During the last three months, 9 analysts shared their evaluations of Vertex (NASDAQ:VERX), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%. Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (LSE:0A3L) from Outperform to Market Perform. There are 474 funds or institutions reporting positions in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings throughout the application software sector at the start of 2025.

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

DA Davidson analyst William Jellison initiated coverage of Vertex (VERX) with a Buy rating and $62 price target Vertex “exhibits several characteristics exemplifying sustained value-capture and ...